Shots:

• The collaboration leverages NuProbe's BDA technology and QIAGEN’s SPE technology to develop NGS based cancer diagnostic tests for non-invasive liquid biopsy. Integration of both the technologies will enable an accurate & affordable analysis of DNA mutations with low variant allele fractions
• The partners will initially focus on developing research use only products for clinical researchers in oncology and may further work on other commercial products in the future
• Additionally- NuProbe has completed five CE IVD registrations for diagnostic products- including liquid biopsy mutation detection kits for the EGFR and BRAF genes

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: QIAGEN